R Squared’s ImmunityBio IBRX Stock Holding History

R Squared’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$147K	Buy	+16,737	New	+$127K	0.08%	370
2026 Q1	–	Sell	-35,180	Closed	-$69.7K	–	573
2025 Q4	$69.7K	Buy	35,180 +17,710	+101%	+$40.1K	0.03%	438
2025 Q3	$43K	Buy	+17,470	New	+$45K	0.02%	502

Other funds holding IBRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

R Squared's IBRX Position: Q2 2026 in Review

R Squared opened a new position in ImmunityBio (IBRX) in Q2 2026: 16,737 shares worth $147K. The stake represents 0.08% of the portfolio and ranks #370 among its holdings. This is a return to the name: R Squared previously reported a position in IBRX as recently as Q4 2025.

R Squared first reported a position in IBRX in Q3 2025 and has held it in 3 quarters since. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

R Squared held 16,737 shares of ImmunityBio worth $147K as of Q2 2026.
ImmunityBio was a new R Squared position in Q2 2026.
ImmunityBio made up 0.08% of R Squared's portfolio in Q2 2026, its #370 holding.
R Squared first reported a position in ImmunityBio in Q3 2025 and has held it in 3 quarters since.
405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on R Squared's 13F filing for Q2 2026, filed 5 Aug 2026.